Activity Overview
Follicular lymphoma (FL) is generally incurable but highly treatable, with most patients requiring multiple lines of therapy. The relapsed/refractory (R/R) FL treatment landscape has evolved rapidly, with chimeric antigen receptor (CAR) T-cell therapies, CD20×CD3 bispecific antibodies, and novel combinations including tafasitamab plus R² (lenalidomide and rituximab) and epcoritamab plus R² all expanding the therapeutic armamentarium. As community oncologists navigate this complex landscape, optimal patient selection, treatment sequencing, and timely referral to specialized centers have become critical.
This Community Practice Connection™ program provides an in-depth review of recent advances in the treatment of R/R FL. This unique and engaging multimedia activity is ideal for the community-based clinician. It focuses on practical interpretation of clinical trial data and management strategies for bispecific antibodies, CAR T-cell therapy, BTK inhibitors, and emerging novel combinations in the community oncology setting.
Target Audience
This educational program is directed toward community-based medical oncologists, hematologic oncologists, hematologists, hematopathologists, nurse practitioners, physician assistants, nurses, pharmacists, and other health care professionals involved in the treatment of FL.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Apply guideline recommendations and practice-changing advances to treatment selection in R/R FL
- Analyze evidence for current and emerging therapeutics in the context of sequencing in FL
- Assess data from ongoing studies that impact the evolving treatment paradigms in FL
Lori A. Leslie, MD
Associate Professor of Medicine
Hackensack Meridian School of Medicine
Attending Physician, Lymphoma Division
Director, Indolent Lymphoma and CLL Research Programs
John Theurer Cancer Center
Hackensack, NJ
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: AbbVie, AstraZeneca, BeiGene, Genmab, Kite/Gilead, Lilly.
Krish Patel, MD
Director, Lymphoma Research
Sarah Cannon Research Institute
Nashville, TN
Disclosures: Type (Italic): Advisor, Consultant, Fee for Service Recipient: AbbVie, ADC Therapeutics, AstraZeneca, BeiGene, BMS/Celgene/Juno, Caribou Biosciences, Epizyme, Fate Therapeutics, Genentech, Kite (a Gilead company), Loxo/Lilly, MorphoSys, Pharmacyclics, Seagen, TG Therapeutics, Xencor; Speakers Bureau: AstraZeneca, BMS/Celgene, Kite (a Gilead company), TG Therapeutics; Grant/Research Funding (to institution): Aptevo Therapeutics, AstraZeneca, BMS, Celgene, Curis, Epizyme, Fate Therapeutics, Kite/Gilead, Loxo/Lilly, MEI Pharma, Nurix, Pfizer, Pharmacyclics, Roche/Genentech, Takeda, Trillium Therapeutics, Xencor
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login HereAccreditation/Credit Designation
Physicians’ Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians’ Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 1.25 Contact Hours.
Physicians' Education Resource®, LLC (PER) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
Physicians' Education Resource®, LLC has approved this application-based activity for 1.25 ACPE CE hours UAN # 0661-0000-26-016-H01-P. Eligibility for credits requires full engagement with the enduring activity, completion and submission of the learner NABP ID # and month and day of birth, activity pre/post-session questions, and the post activity evaluation. This UAN # expires August 31, 2027.
Acknowledgment of Commercial Support
This activity is supported by an educational grant from Incyte Corporation, Inc.